ABSTRACT
Background Individuals with Mild Cognitive Impairment (MCI) have more gait variability under dual-task conditions than cognitively healthy adults. However, characteristics associated with this susceptibility of gait to dual-task stress are unknown.
Methods Testing was performed at baseline in the Study of Mental And Resistance Training (SMART). Ninety-three adults with MCI (age 70±6.8 years; 66.6% female) performed a single- and dual-task walk (cognitive distractor=letter fluency), in random order. Linear and non-linear gait variability were measured using force-sensitive insoles. Cognitive performance during dual-tasking was assessed by the number of correct words vocalized. Cognitive function, brain Magnetic Resonance Imaging (MRI), muscle strength, aerobic capacity, body composition, physical and psychosocial function were also assessed as potential correlates of gait dynamics.
Results Gait dynamics worsened during dual-tasking, with decrements in both stride time variability (p<0.001) and detrended fluctuation analysis (DFA) (p=0.001). Lower aerobic capacity and thinner posterior cingulate cortex were associated with greater decrements in DFA (p<0.05). Smaller hippocampal volume, worse psychological well-being and poorer static balance were associated with greater decrements in stride time variability (p<0.05). By contrast, cognitive performance did not change under dual-task conditions compared to seated testing (p=0.13).
Conclusions Under dual-task conditions, participants with MCI preserved their cognitive performance at the expense of gait stability. Decrements in dual-tasking gait were associated with lower aerobic fitness, balance, psychological well-being, and brain volume in cognitively-relevant areas of the posterior cingulate and hippocampus, all potentially modifiable characteristics. Trials of targeted interventions are needed to determine the potential plasticity of gait variability in high-risk cohorts.
Competing Interest Statement
MV has previously received honoraria for speaking at Pfizer and The Brain Department Pty Ltd sponsored events, and receives industry in-kind support from collaborating software companies Synaptikon, Cambridge Brain Sciences and COGSTATE. He is also scientific founder of University of Sydney spin-out company Skin2Neuron Pty Ltd, from which he receives consulting fees and in which he has a financial interest in through the University’s shareholding and IP Policy. These interests have no relationship to this work. HB is an Advisory Board member for Nutricia Australia. BB is a member of advisory boards and/or gave presentations for the following companies, for which he has received honoraria: AstraZeneca, Lundbeck, Pfizer, Servier, and Wyeth. PS has received honoraria from Biogen Australia Pty.
Clinical Trial
ANZCTRN1260800048932
Clinical Protocols
https://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-11-19
Funding Statement
This study was funded by a National Health and Medical Research Council of Australia Dementia Research Grant (512672). Additional funding for a research assistant position was sourced from the NHMRC Program (568969), and the project was supported by the University of Sydney and University of New South Wales. MV was supported by a University of New South Wales Vice Chancellor’s Fellowship and a NHMRC Clinical Career Development Fellowship (1004156).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Data are not available
